https://www.selleckchem.com/products/Axitinib.html
Results of randomized controlled trials (RCT) do not provide definite guidance for secondary prevention after ischemic stroke (IS)/transient ischemic attack (TIA) attributed to patent foramen ovale (PFO). No recommendations can be made for patients 60 years. We aimed to compare interventional and medical PFO-management in cryptogenic IS/TIA patients, including patients 60 years. Prospective case series including consecutive cryptogenic IS/TIA patients with PFO at Tuebingen university stroke unit, Germany. 'PFO-closure' was re
Like
Comment
Share
